Among these, VEGF is considered as the most potent pro-angiogenic factor, as multiple pivotal trials have shown the effectiveness of anti-VEGF therapies in nAMD (Rosenfeld et al., 2006; Brown et al., 2009), DME (Brown et al., 2013), retinal vein occlusions (Brown et al., 2010; Campochiaro et al., 2010; Yiu et al., 2020c), and ROP (Stahl et al., 2019). The gene discussed is VEGFA; the disease is retinal vein occlusion.